We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+55.74%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$531M
AUM Growth
+$61.3M
Cap. Flow
-$27.5M
Cap. Flow %
-5.17%
Top 10 Hldgs %
72.14%
Holding
37
New
3
Increased
6
Reduced
15
Closed
8

Top Buys

Rank Stock Value
1
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$11.3M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$10.3M
3
IMDZ
Immune Design Corp.
IMDZ
+$8.77M
4
OMED
OncoMed Pharmaceuticals, Inc.
OMED
+$5.5M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$5.13M

Top Sells

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$19.8M
2
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$9.53M
3
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$8.21M
4
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$8M
5
ARRY
Array Biopharma Inc
ARRY
+$6.96M

Sector Composition

Rank Sector Weight
1 Healthcare 77.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
1
DELISTED
Blueprint Medicines
BPMC
$82.1M 15.48%
2,765,080
-130,171
-4% -$3.23M
CCXI
2
DELISTED
ChemoCentryx, Inc.
CCXI
$48.7M 9.18%
8,064,019
-118,033
-1% -$558K
CYTK icon
3
Cytokinetics
CYTK
$10.9B
$45.9M 8.64%
4,997,071
+7,853
+0.2% +$82K
ARRY
4
DELISTED
Array Biopharma Inc
ARRY
$43.6M 8.22%
6,461,186
-1,799,711
-22% -$6.96M
CASC
5
DELISTED
Cascadian Therapeutics, Inc.
CASC
$30.8M 5.81%
3,133,228
– –
FWP
6
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$29.1M 5.49%
198,265
-5,251
-3% -$739K
CLCD
7
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$29.1M 5.49%
+763,300
New +$11.3M
CNCE
8
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$27.5M 5.19%
2,723,210
-32,108
-1% -$351K
XENE icon
9
Xenon Pharmaceuticals
XENE
$6.2B
$25.2M 4.75%
3,108,905
+1,333,333
+75% +$10.3M
OMED
10
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$20.7M 3.9%
1,812,005
+472,669
+35% +$5.5M
CBIO
11
Crescent Biopharma
CBIO
$555M
$17.3M 3.27%
24,263
-211
-0.9% -$161K
CTIC
12
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$16.8M 3.16%
4,479,694
– –
TBRA
13
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$15.9M 2.99%
399,433
-853,968
-68% -$9.53M
ALPN
14
DELISTED
Alpine Immune Sciences Inc
ALPN
$13.9M 2.62%
427,418
-54,193
-11% -$1.32M
ARQL
15
DELISTED
Arqule Inc
ARQL
$13.2M 2.5%
7,400,128
-50,000
-0.7% -$79.3K
CTMX icon
16
CytomX Therapeutics
CTMX
$714M
$9.28M 1.75%
591,813
-14,325
-2% -$173K
IMDZ
17
DELISTED
Immune Design Corp.
IMDZ
$9.1M 1.71%
+1,200,000
New +$8.77M
ONCT
18
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$9.01M 1.7%
8,223
– –
INFI
19
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$8.03M 1.51%
5,149,644
-34,956
-0.7% -$53.7K
PTGX icon
20
Protagonist Therapeutics
PTGX
$8.92B
$7.92M 1.49%
+375,000
New +$5.13M
ESPR
21
DELISTED
Esperion Therapeutics
ESPR
$6.84M 1.29%
493,872
-5,270
-1% -$59.7K
KDNY
22
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$6.23M 1.17%
100,231
-2,490
-2% -$176K
VIRX
23
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.19M 0.6%
20,867
-2,053
-9% -$290K
OREX
24
DELISTED
Orexigen Therapeutics, Inc.
OREX
$2.44M 0.46%
734,976
+209,766
+40% +$792K
FLNA
25
Filana Therapeutics
FLNA
$46.4M
$2.28M 0.43%
325,507
+18,377
+6% +$304K
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2016 Portfolio in Review

As of Q3 2016, BVF Inc held 37 positions worth $531M, up 13% from $469M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

BVF Inc withdrew a net $27.5M in Q3 2016, closing 8 positions and reducing 15 holdings. Its most notable exit was Ionis Pharmaceuticals, an estimated $19.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 70% a quarter earlier.

Against the trend, BVF Inc opened a new position in CoLucid Pharmaceuticals, Inc. worth $29.1M.

  • BVF Inc's largest Q3 2016 buy was CoLucid Pharmaceuticals, Inc.: 763,300 shares worth $29.1M.
  • BVF Inc added most to Xenon Pharmaceuticals in Q3 2016, an estimated $10.3M increase.
  • BVF Inc's biggest Q3 2016 reduction was Tobira Therapeutics, Inc. Common Stock, cutting an estimated $9.53M.
  • BVF Inc fully exited Ionis Pharmaceuticals in Q3 2016, selling an estimated $19.8M.
  • BVF Inc's ten largest holdings make up 72% of its $531M portfolio in Q3 2016.
  • BVF Inc opened 3 new positions and closed 8 in Q3 2016.
  • BVF Inc's portfolio value rose 13% quarter-over-quarter to $531M.

Based on BVF Inc's 13F filing for Q3 2016, filed 14 Nov 2016.